Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.
Year: 2016
Type: article
Abstract: Multiple myeloma (MM) pathogenesis may broadly be defined as a malignancy of terminally differentiated B cells that produce a complete and/or partial (light chain) monoclonal immunoglobulin protein.1 Although clinical manifestations may present in diverse ways, the cardinal signs—hypercalcemia, renal in sufficiency, anemia, and bone lesions (collectively known as “CRAB” signs)—are quite common and result from end-organ damage caused by myeloma mass effect or inflammatory proteins.2 MM represents 1.6% of all new cancer cases in the United States, comprising approximately 10% of hematological malignancies.3 Despite research and development, MM remains largely incurable, with a five-year survival rate of 46.6%.2,3
Carfilzomib (Kyprolis, Amgen) is a proteasome inhibitor indicated for the treatment of patients with relapsed or refractory MM.4 The Food and Drug Administration (FDA) awarded carfilzomib accelerated approval in July 2012 as monotherapy.5 The medication is now indicated for use as a single agent in patients with relapsed or refractory MM who have received one or more lines of therapy.4 In July 2015, the FDA approved carfilzomib as a component of combination therapy.6 It is currently indicated with dexamethasone or with lenalidomide (Revlimid, Celgene) plus dexamethasone for the treatment of relapsed or refractory MM in patients who have received one to three lines of prior treatment.4
Source: PubMed Central
Authors: Galina Perel, Joshua Bliss, Christan M Thomas
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2418349659
